BioSpace News Archive

Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) announced today positive Phase 2a top-line clinical trial results for the RTX program.

United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced that The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute, part of the University of Utah health care system in Salt Lake City, has installed another United Imaging PET/CT scanner.

Synaptogenix, Inc. (Nasdaq: SNPX) (“Synaptogenix” or the “Company”), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced findings from an independent study demonstrating the potential for Bryostatin-1 as a treatment strategy for amyotrophic lateral sclerosis (“ALS”), also known as Lou Gehrig’s Disease.

Eminence Biotechnology Co., Ltd. is delighted to announce that its state-of-the-art facility for the commercial production of cell culture media is now fully operational.

Strata Oncology, Inc. today announced new data showing its proprietary biomarker algorithm, Immunotherapy Response Score (IRS), supports informed clinical decisions for first-line treatment of patients with non-small cell lung cancer (NSCLC) beyond the standard of care biomarker PD-L1 immunohistochemistry (IHC).

A new prospective, multicenter study, recently published in The Lancet Neurology has revealed the significant prognostic value of the Neurological Pupil index™ (NPi®), measured using the NeurOptics NPi Pupillometer, in evaluating disease progression and predicting outcomes for patients with acute brain injury.

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies

Coya Therapeutics, Inc. announced that Dr. Phil Campbell, Professor of Biomedical Engineering at CMU, presented his talk, “Rapid Functionalization of Treg Exosomes for Targeted Immunotherapy” at the 5th Exosome Based Therapeutic Development Summit in Boston, MA this morning (September 7, 2023).

Scipher Medicine Corporation today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC), and Centers for Medicare and Medicaid Services (CMS) published a local coverage determination (LCD) for molecular biomarker testing to guide targeted therapy selection in rheumatoid arthritis (RA) patients.

Sentynl herapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases, announced that data evaluating NULIBRY® (fosdenopterin) for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A were presented at the 2023 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Meeting on Aug. 30 in Jerusalem.